<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057600</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-007</org_study_id>
    <nct_id>NCT03057600</nct_id>
  </id_info>
  <brief_title>Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced TNBC</brief_title>
  <official_title>A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in
      patients of African ancestry and non-African ancestry with advanced triple negative breast
      cancer. Multiple single-arm cohorts will be enrolled in which 800 mg BID CB-839 will be
      administered in combination with the full approved dose of paclitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in
      patients of African ancestry and non-African ancestry with advanced triple negative breast
      cancer. Multiple single-arm cohorts will be enrolled in which 800 mg BID CB-839 will be
      administered in combination with the full approved dose of paclitaxel.

      Patients will be enrolled into 4 cohorts, as follows:

        -  Cohort 1: patients of African ancestry with 2 or more lines of prior therapy for
           metastatic disease

        -  Cohort 2: patients of African ancestry with no prior lines of therapy for metastatic
           disease

        -  Cohort 3: same as cohort 1 but in patients of non-African ancestry

        -  Cohort 4: same as cohort 2 but in patients of non-African ancestry
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be assigned to one of 4 arms depending on the number of prior lines of therapy they have received and whether or not they have African ancestry</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 15 months]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Approximately 18 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Type, incidence, severity, seriousness, and relatedness of adverse events per CTCAE v.4.0</measure>
    <time_frame>Approximately 15 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - African ancestry, 3rd line+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention = Pac-CB combination
Patients must self-identify as African ancestry (AA; includes African American).
At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.
Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.
Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - African ancestry, 1st line</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention = Pac-CB combination
Patients must self-identify as African ancestry (includes African American).
No prior systemic therapy for advanced or metastatic disease.
Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was &gt; 12 mo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Non-AA, 3rd line+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention = Pac-CB combination
Patients do not self-identify as African ancestry.
Otherwise have the same criteria as Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Non-AA, 1st line</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention = Pac-CB combination
Patients do not self-identify as African ancestry.
Otherwise have the same criteria as Cohort 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pac-CB</intervention_name>
    <description>CB-839 administered as oral tablets twice daily (BID) in combination with standard weekly paclitaxel in 28-day cycles</description>
    <arm_group_label>Cohort 1 - African ancestry, 3rd line+</arm_group_label>
    <arm_group_label>Cohort 2 - African ancestry, 1st line</arm_group_label>
    <arm_group_label>Cohort 3 - Non-AA, 3rd line+</arm_group_label>
    <arm_group_label>Cohort 4 - Non-AA, 1st line</arm_group_label>
    <other_name>Glutaminase inhibitor</other_name>
    <other_name>Taxane</other_name>
    <other_name>CB-839</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Meets criteria for 1 of the 4 defined study cohorts

          -  TNBC defined as ER and PR negative (&lt;1%) and HER-2 negative (FISH negative or IHC
             0-1+)

          -  Metastatic disease or locally-advanced disease not amenable to curative intent
             treatment

          -  Adequate hepatic, renal, cardiac, and hematologic function

          -  ECOG performance status 0-1

          -  Recovery to baseline or ≤ Grade 1 CTCAE ver.4.0

        Key Exclusion Criteria:

          -  Known brain metastases or CNS cancer unless adequately treated with radiotherapy
             and/or surgery and stable for ≥ 2 mo

          -  Unable to receive oral medications

          -  Known hypersensitivity to Cremophor®-based agents

          -  Major surgery within 28 days of C1D1
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Whiting, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Administrator</last_name>
    <phone>650-870-1000</phone>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Brimingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Caterinicchia</last_name>
    </contact>
    <contact_backup>
      <email>val7@uab.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of South Alabama, Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Norden, MD</last_name>
      <phone>251-665-8000</phone>
      <email>cwisemannorden@health.southalabama.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sachin Pai, MD</last_name>
      <phone>251-665-8000</phone>
      <email>spai@health.southalabama.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Silber</last_name>
      <phone>203-737-7059</phone>
      <email>andrea.silber@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Trisha Burrello</last_name>
      <email>trisha.burrello@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Silber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University - Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Castle</last_name>
      <phone>202-687-2209</phone>
      <email>bickmorj@georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Antonella Noviella</last_name>
      <phone>202-784-3923</phone>
      <email>noviella@georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Filipa Lynce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gouled Ahmed</last_name>
      <phone>202-877-9374</phone>
      <email>Gouled.A.Ahmed@medstar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Administrator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Borisenko</last_name>
      <phone>813-745-4398</phone>
      <email>lynn.borisenko@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hatem Soliman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer and Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hodgson</last_name>
      <phone>706-353-2990</phone>
      <phone_ext>279</phone_ext>
      <email>jhodgson@universitycancer.com</email>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute - Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30332</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keerthi Gogineni, MD</last_name>
      <phone>404-778-5994</phone>
      <email>keerthi.gogineni@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chelsea M Johnson Roberts</last_name>
      <phone>404-778-6575</phone>
      <email>chelsea.m.johnson@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Keerthi Gogineni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Parker</last_name>
      <email>kparker@ngoc.com</email>
    </contact>
    <investigator>
      <last_name>Steve McCune, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Woolery, RN, OCI</last_name>
      <phone>504-842-0275</phone>
      <email>amanda.woolery@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>John Cole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institute at Franklin Square</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Flack, RN</last_name>
      <phone>443-777-7364</phone>
      <email>Jean.Flack@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Sally Brown</last_name>
      <phone>443-777-7962</phone>
      <email>sally.brown@medstar.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Vallieres, BSN, RN, OCN</last_name>
      <phone>313-916-2438</phone>
      <email>PVALLIE9@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Haythem Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra King, RN</last_name>
      <email>debra.king@health.slu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kevin T Palka, MD</last_name>
      <phone>314-577-8854</phone>
      <email>Kevin.palka@health.slu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin T Palka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JTCC at Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aretha DiSalvo</last_name>
      <phone>551-996-8258</phone>
      <email>Aretha.disalvo@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Deena Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Kalinsky, MD</last_name>
      <phone>212-305-5098</phone>
      <email>kk2693@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <phone>212-305-1945</phone>
    </contact_backup>
    <investigator>
      <last_name>Kevin Kalinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Matthai</last_name>
      <phone>215-349-8740</phone>
      <email>alice.matthai@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Angela DeMichelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee Womens Hospital - UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather DiCostanzo</last_name>
      <phone>412-641-6068</phone>
      <email>follhl@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carol Kagemann</last_name>
      <phone>412-642-2258</phone>
      <email>kagemannca@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Brufsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Patel, RN</last_name>
      <email>Stephanie.patel@choasc.com</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Morrill</last_name>
      <phone>843-577-6957</phone>
      <email>ashley.morrill@choasc.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Orcutt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System (GHS) Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Norris</last_name>
      <phone>864-242-2762</phone>
      <email>GNorris@ghs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fletcher</last_name>
      <email>afletcher@westclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudette Foreman</last_name>
      <phone>713-798-1999</phone>
      <email>caforema@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Julia R. Nangia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Samuel, RN</last_name>
      <phone>713-792-9559</phone>
      <email>cosamuel@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Bora Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Parker</last_name>
      <phone>253-306-0532</phone>
      <email>sparker@southsoundcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Research Department</last_name>
      <phone>253-428-8750</phone>
      <email>researchmain@nwmsonline.comresearch@southsoundcare.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical College of Wisconsin Cancer Center</last_name>
      <phone>414-805-8900</phone>
      <email>cccto@mcw.edu</email>
    </contact>
    <contact_backup>
      <phone>1-866-680-0505</phone>
      <phone_ext>8900</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Sailaja Kamaraju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.calithera.com</url>
    <description>Company Website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>African ancestry</keyword>
  <keyword>African American</keyword>
  <keyword>CB-839</keyword>
  <keyword>Glutaminase Inhibitor</keyword>
  <keyword>Glutaminase</keyword>
  <keyword>TNBC</keyword>
  <keyword>Tumor Metabolism</keyword>
  <keyword>Glutamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

